# A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

> **NCT05484011** · PHASE1 · TERMINATED · sponsor: **HiberCell, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Metastatic Pancreatic Adenocarcinoma

## Interventions

- **BIOLOGICAL:** odetiglucan
- **BIOLOGICAL:** CDX-1140

## Key facts

- **NCT ID:** NCT05484011
- **Lead sponsor:** HiberCell, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-12-15
- **Primary completion:** 2024-03-04
- **Final completion:** 2024-03-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** sponsor decision
- **Last updated:** 2024-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05484011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05484011, "A Maintenance Therapy Study of Odetiglucan With CDX-1140 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05484011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*